Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6

Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6

Baird analyst Joel Beatty maintains Cardiff Oncology (NASDAQ:CRDF) with a Outperform and lowers the price target from $9 to $6.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Baird analyst Joel Beatty maintains Cardiff Oncology (NASDAQ:CRDF) with a Outperform and lowers the price target from $9 to $6.

Stephens & Co. Downgrades Ping Identity Holding to Equal-Weight

By Benzinga Newsdesk

August 4, 8:14 AM

Stephens & Co. analyst Brian Colley downgrades Ping Identity Holding (NYSE:PING) from Overweight to Equal-Weight.

PING

Tesla’s Image Suffers Blow: EV Giant Drops 50 Spots In List Of Most Reputable US Brands

By Shanthi Rexaline

May 24, 8:56 AM

A YouGov survey in late 2022 showed that the approval rating for Tesla, Inc. (NASDAQ:TSLA) electric vehicle brand…

Vodafone-CK Hutchison Merger Announcement May Come By Next Week: Report

By Lekha Gupta

June 7, 5:18 AM

Vodafone Group PLC (NASDAQ: VOD) and CK Hutchison Holdings Ltd (OTC: CKHUF) are said to be in the final stages of agreeing to combine their U.K. businesses.

CKHUF

Analyst Ratings

Critical Insights From Autoliv Analyst Ratings: What You Need To Know

By Benzinga Insights

January 30, 8:00 AM

Autoliv (NYSE:ALV) has been analyzed by 4 analysts in the last three months, revealing a diverse range of…

ALV

Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6

Related Posts

Stephens & Co. Downgrades Ping Identity Holding to Equal-Weight

Tesla’s Image Suffers Blow: EV Giant Drops 50 Spots In List Of Most Reputable US Brands

Vodafone-CK Hutchison Merger Announcement May Come By Next Week: Report

Critical Insights From Autoliv Analyst Ratings: What You Need To Know